Abstract:Background: KCNH family of potassium channels is responsible for diverse physiological functions ranging from the regulation of neuronal excitability and cardiac contraction to the regulation of cancer progression. KCNH channels contain a Per-Arn-Sim (PAS) domain in their N-terminal and cyclic nucleotide-binding homology (CNBH) domain in their C-terminal regions. These intracellular domains shape the function of KCNH channels and are important targets for drug development. Methods: Here we describe a surface plasmon resonance (SPR)-based screening method aimed in identifying small molecule binders of PAS and CNBH domains for three KCNH channel subfamilies: ether-à-go-go (EAG), EAG-related gene (ERG), and EAG-like K+ (ELK). The method involves purification of the PAS and CNBH domains, immobilization of the purified domains on the SPR senor chip and screening small molecules in a chemical library for binding to the immobilized domains using changes in the SPR response as a reporter of the binding. The advantages of this method include low quantity of purified PAS and CNBH domains necessary for the implementation of the screen, direct assessment of the small molecule binding to the PAS and CNBH domains and easiness of assessing KCNH subfamily specificity of the small molecule binders. Results: Using the SPR-based method we screened the Spectrum Collection Library of 2560 compounds against the PAS and CNBH domains of the three KCNH channel subfamilies and identified a pool of small molecules that bind to the PAS or CNBH domains. To further evaluate the effectiveness of the screen we tested the functional effect of one of the identified mEAG PAS domain specific small molecule binders on currents recorded from EAG channels. Undecylenic acid inhibited currents recorded from EAG channels in a concentration-dependent manner with IC50 of ~ 1 μM. Conclusion: Our results show that the SPR-based method is well suited for identifying small molecule binders of KCNH channels and can facilitate drug discovery for other ion channels as well.

Identification of undecylenic acid as EAG channel inhibitor using surface plasmon resonance-based screen of KCNH channels

Identification of Small-Molecule Ion Channel Modulators in C. Elegans Channelopathy Models.

Automated Tight Seal Electrophysiology for Assessing the Potential Herg Liability of Pharmaceutical Compounds

Molecular mechanism of EAG1 channel inhibition by imipramine binding to the PAS domain

AI-Based Discovery and CryoEM Structural Elucidation of a K Channel Pharmacochaperone

Non-invasive hERG channel screening based on electrical impedance tomography and extracellular voltage activation (EIT-EVA)

Identification of a Novel, Small Molecule Partial Agonist for the Cyclic AMP Sensor, EPAC1

A Small-Molecule Activation Mechanism That Directly Opens the KCNQ2 Channel

Early identification of hERG liability in drug discovery programs by automated patch clamp

Structural Insights into the Atomistic Mechanisms of Action of Small Molecule Inhibitors Targeting the KCa3.1 Channel Pore

Screening Technologies for Inward Rectifier Potassium Channels: Discovery of New Blockers and Activators

In Silico Assisted Identification, Synthesis, and In Vitro Pharmacological Characterization of Potent and Selective Blockers of the Epilepsy-Associated KCNT1 Channel

The Gating Charge Pathway of an Epilepsy-Associated Potassium Channel Accommodates Chemical Ligands

Structure-based discovery of potassium channel blockers from natural products: virtual screening and electrophysiological assay testing.

A thallium transport FLIPR-based assay for the identification of KCC2-positive modulators

Molecular dynamics of hERG channel: insights into understanding the binding of small molecules for detuning cardiotoxicity

Validation of an Atomic Absorption Rubidium Ion Efflux Assay for KCNQ/M-channels Using the Ion Channel Reader 8000.

Automated Patch Clamp Recordings of GPCR-Gated Ion Channels: Targeting the MC4-R/Kir7.1 Potassium Channel Complex

Structural insights into binding of therapeutic channel blockers in NMDA receptors

Mechanism-specific Assay Design Facilitates the Discovery of Nav1.7-selective Inhibitors

Discovery of Potent and Selective Blockers Targeting the Epilepsy-Associated KNa1.1 Channel.